Chikungunya overview: Difference between revisions
| Line 25: | Line 25: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Chikungunya was first described in Tanzania, Africa in 1952. Chikungunya outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first local transmission of chikungunya [[virus]] in the Americas was identified in Caribbean countries and territories. Local transmission means that [[mosquitoes]] in the area have been infected with the [[virus]] and are spreading it to people. | Chikungunya was first described in Tanzania, Africa in 1952. Chikungunya outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first local transmission of chikungunya [[virus]] in the Americas was identified in Caribbean countries and territories. Local transmission means that [[mosquitoes]] in the area have been infected with the [[virus]] and are spreading it to people. | ||
==Risk Factors== | |||
People who travel to the Caribbean, Africa, Asia, islands in the Indian Ocean and Western Pacific are at risk as the [[virus]] is present in many of these areas. People at risk for more severe disease include [[newborns]] infected around the time of birth, older adults (≥65 years), and people with medical conditions such as [[high blood pressure]], [[diabetes]], or [[heart disease]]. | |||
==Natural History, Complications and Prognosis== | |||
Complications are rare and include [[uveitis]], [[retinitis]], [[myocarditis]], [[hepatitis]], [[nephritis]], [[bullous]] skin lesions, [[hemorrhage]], [[meningoencephalitis]], [[myelitis]], [[Guillain-Barré syndrome]], and [[cranial nerve palsies]]. Persons at risk for severe disease include [[neonates]] exposed intrapartum, older adults (e.g., > 65 years), and persons with underlying medical conditions (e.g., [[hypertension]], [[diabetes]], or [[cardiovascular disease]]). Most patients recover uneventfully, but variable proportions of patients may have persistent [[arthralgias]] ([[joint pains]]) for months to years. | |||
==Diagnosis== | ==Diagnosis== | ||
Revision as of 14:06, 16 June 2014
|
Chikungunya Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chikungunya overview On the Web |
|
American Roentgen Ray Society Images of Chikungunya overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Chikungunya virus (CHIKV) is an arthropod-borne virus, of the genus Alphavirus, that is transmitted to humans by virus-carrying Aedes mosquitoes.[1]
CHIKV is transmitted similarly to dengue fever and causes an illness with an acute febrile phase lasting two to five days, followed by a longer period of joint pains in the extremities; this pain may persist for years in some cases.[2][3] The best means of prevention is overall mosquito control and in addition, the avoidance of bites by any infected mosquitoes. There is no specific treatment currently available but medications can be used to reduce symptoms.
Historical Perspective
The name chikungunya is derived from the Makonde word meaning "that which bends up" in reference to the stooped posture developed as a result of the arthritic symptoms of the disease. The disease was first described by Marion Robinson[4] and W.H.R. Lumsden[5] in 1955, following an outbreak on the Makonde Plateau, along the border between Tanganyika and Mozambique, in 1952. Chikungunya is closely related to O'nyong'nyong virus[6].
Pathophysiology
Chikungunya virus (CHIKV) belongs to the alphavirus genus of the Togaviridae family and is transmitted by mosquito bites. Both innate and adaptive immunity are involved in the pathogenesis of CHIKV infection.
Causes
Chikungunya virus is an alphavirus with a positive sense single-stranded RNA genome of approximately 11.6kb. It is a member of the Semliki Forest Virus complex and is closely related to Ross River Virus, O’Nyong Nyong virus and Semliki Forest Virus.[7] In the United States it is classified as a Category C priority pathogen[8] and work requires Biosafety Level 3 precautions.[9]
Human epithelial, endothelial, primary fibroblasts and monocyte-derived macrophages are permissive for chikungunya virus in vitro and viral replication is highly cytopathic but susceptible to type I and II interferon.[10] In vivo, chikungunya virus appears to replicate in fibroblasts, skeletal muscle progenitor cells and myofibers.[11][12]
Differential Diagnosis
Chikunguyna must be differentiated from other diseases that present with flu like symptoms such as fever, headache, fatigue, joint aches or arthralgias, myalgias. Diseases with similar symptoms include dengue, influenza, measles, rubella, malaria, and yellow fever.
Epidemiology and Demographics
Chikungunya was first described in Tanzania, Africa in 1952. Chikungunya outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories. Local transmission means that mosquitoes in the area have been infected with the virus and are spreading it to people.
Risk Factors
People who travel to the Caribbean, Africa, Asia, islands in the Indian Ocean and Western Pacific are at risk as the virus is present in many of these areas. People at risk for more severe disease include newborns infected around the time of birth, older adults (≥65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.
Natural History, Complications and Prognosis
Complications are rare and include uveitis, retinitis, myocarditis, hepatitis, nephritis, bullous skin lesions, hemorrhage, meningoencephalitis, myelitis, Guillain-Barré syndrome, and cranial nerve palsies. Persons at risk for severe disease include neonates exposed intrapartum, older adults (e.g., > 65 years), and persons with underlying medical conditions (e.g., hypertension, diabetes, or cardiovascular disease). Most patients recover uneventfully, but variable proportions of patients may have persistent arthralgias (joint pains) for months to years.
Diagnosis
Symptoms
The common symptoms of chikungunya include fever, petechial or maculopapular rash and arthralgia or arthritis affecting multiple joints.
Treatment
Medical Therapy
There is no specific antiviral therapy and the treatment is symptomatic. Assess hydration and hemodynamic status and provide supportive care as needed
Prevention
- No vaccine exists to prevent chikungunya virus infection or disease.
- Avoiding mosquito bites is the best way to prevent chikungunya virus infection.
- The mosquitoes that spread the chikungunya virus bite mostly during the daytime.
- The most effective means of prevention are those that protect against any contact with the disease-carrying mosquitoes. These include using insect repellent containing DEET or permethrin, wearing long sleeves and trousers (pants), and securing screens on windows and doors. It's also important to empty stagnant water where mosquitoes breed.
References
- ↑ Lahariya C, Pradhan SK (December 2006). "Emergence of chikungunya virus in Indian subcontinent after 32 years: A review" (PDF). J Vector Borne Dis. 43 (4): 151–60. PMID 17175699.
- ↑ Powers AM, Logue CH (September 2007). "Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus". J. Gen. Virol. 88 (Pt 9): 2363–77. doi:10.1099/vir.0.82858-0. PMID 17698645.
- ↑ Sourisseau M, Schilte C, Casartelli N; et al. (June 2007). "Characterization of reemerging chikungunya virus". PLoS Pathog. 3 (6): e89. doi:10.1371/journal.ppat.0030089. PMC 1904475. PMID 17604450.
- ↑ Robinson Marion (1955). "An Epidemic of Virus Disease in Southern Province, Tanganyika Territory, in 1952-53; I. Clinical Features". Trans Royal Society Trop Med Hyg. 49 (1): 28–32.
- ↑ Lumsden WHR (1955). "An Epidemic of Virus Disease in Southern Province, Tanganyika Territory, in 1952-53; II. General Description and Epidemiology". Trans Royal Society Trop Med Hyg. 49 (1): 33–57. Check date values in:
|year=(help) - ↑ Vanlandingham DL, Hong C, Klingler K, Tsetsarkin K, McElroy KL, Powers AM, Lehane MJ, Higgs S (2005). "Differential infectivities of o'nyong-nyong and chikungunya virus isolates in Anopheles gambiae and Aedes aegypti mosquitoes". Am J Trop Med Hyg. 72 (5): 616–21. PMID 15891138. Check date values in:
|year=(help) - ↑ Powers, AM (Nov 2001). "Evolutionary relationships and systematics of the alphaviruses". Journal of Virology. 75 (21): 10118–31. doi:10.1128/JVI.75.21.10118-10131.2001. PMC 114586. PMID 11581380. Unknown parameter
|coauthors=ignored (help) - ↑ "NIAID Category A, B, and C Priority Pathogens". Retrieved 1 January 2014.
- ↑ "Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition" (PDF). Retrieved 1 January 2014.
- ↑ Sourisseau, M (Jun 2007). "Characterization of reemerging chikungunya virus". PLoS Pathogens. 3 (6): e89. doi:10.1371/journal.ppat.0030089. PMC 1904475. PMID 17604450. Unknown parameter
|coauthors=ignored (help) - ↑ Schilte, C (Feb 15, 2010). "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells". The Journal of experimental medicine. 207 (2): 429–42. doi:10.1084/jem.20090851. PMC 2822618. PMID 20123960. Unknown parameter
|coauthors=ignored (help) - ↑ Rohatgi, A (Dec 11, 2013). "Infection of myofibers contributes to the increased pathogenicity during infection with an epidemic strain of Chikungunya Virus". Journal of Virology. 88 (5): 2414–25. doi:10.1128/JVI.02716-13. PMID 24335291. Unknown parameter
|coauthors=ignored (help)